➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Merck
Medtronic
AstraZeneca

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Litigation Details for Endo Pharmaceuticals Inc. v. Actavis Inc. (S.D.N.Y. 2012)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Endo Pharmaceuticals Inc. v. Actavis Inc. (S.D.N.Y. 2012)

Docket   Start Trial Date Filed 2012-12-11
Court District Court, S.D. New York Date Terminated
Cause 35:145 Civil Action to Obtain Patent Assigned To Thomas Poole Griesa
Jury Demand None Referred To
Parties ACTAVIS INC.; ACTAVIS SOUTH ATLANTIC LLC; ENDO PHARMACEUTICALS INC.
Patents 6,277,384; 6,294,195; 6,340,475; 6,495,155; 6,514,531; 7,276,250; 7,851,482; 8,114,383; 8,192,722; 8,309,060; 8,309,122; 8,329,216; RE35,224
Attorneys Blake Greene; Brian Matthew Goldberg; Carl Gismervig; Charles Alan Weiss; Eric Harold Yecies; George G. Gordon; Howard Suh; Jeffrey Thomas Fisher; Jonathan D Loeb; Joshua Isaac Sherman; Martin J. Black; Micheal Bradley Eisenberg; Nicholas Peter Chiara; Robert D Rhoad; Sharon K. Gagliardi; Thomas Paul Lihan
Firms Dechert; Dechert LLP; Dechert LLP (PHILADELPHIA), Cira Centre; Dechert LLP (TX); Dechert LLP, Cira Centre; Dechert, LLP (NJ); Dechert, LLP (NYC); Holland & Knight LLP (NY); Sharon K. Gagliardi
Link to Docket External link to docket
Small Molecule Drugs cited in Endo Pharmaceuticals Inc. v. Actavis Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Endo Pharmaceuticals Inc. v. Actavis Inc.
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Endo Pharmaceuticals Inc. v. Actavis Inc. (S.D.N.Y. 2012)

Date Filed Document No. Description Snippet Link To Document
2012-12-11 1 6,261,599 Bi 7/2001 osmack etal. EP 319243 Ai 6/1939 6,277,384 Bi 312001 Kail<o mt EP 0360562 Bz 3/1990 6,…fm United States Patent go Patent No.= US 8,329,216 Bz Kao et al. (45) Date of Patent: *})ec. 11, 2012…of time THE PATENTS 14. On December 14, 2010, the PTO duly and legally issued U.S. Patent No. 7,85l,482…the ’482 Patent is attached as Exhibit A. 1`5. j Endo has acquired full title to the ’482 Patent, and is…and assignee of the ’482 Patent. 16. lnformation regarding the Endo ’482 Patent Was submitted to FDA for External link to document
2015-08-18 107 of patents and patent claims asserted. See, e.g., Stipulation and Order Re U.S. Patent 7,851,482 (Doc…Agreement was executed, JMI was awarded a patent, Number 7,851,482, concerning a new, low toxicity formulation… There are three patents-in-suit. Endo owns two of the patents, United States patent numbers 8,309,1228,309,122 (“the ’122 Patent”) and 8,329,216 (“the ’216 Patent”). These patents recite a controlled release …Grünenthal owns the third patent, United States Patent Number 8,309,060 (“the ’060 Patent”), which External link to document
2014-03-31 51 asserted patents because the previously licensed U.S. Patent No. 7,276,250 (’250 patent) claims … “Opana® ER Patents” as U.S. Patent Nos. 5,662,933, 5,958,456, and 7,276,250. Id. § 1.20. …asserted patents, U.S. Patent Nos. 8,309,122 (the ’122 patent) and 8,329,216 (the ’216 patent), are…(c) any patents resulting from the reissue or reex- amination of patents or patent application…2716 (“Endo’s ’122 patent and ’216 patent are continuations of a patent called out by number External link to document
2015-03-11 87 122 patent”), 8,329,216 (“the ’216 patent”), and Grünenthal’s United States Patent Nos. 8,114,383 (“the…............ 17 IV. THE ENDO PATENTS (THE ’122 AND ’216 PATENTS).................................…Infringe the Endo Patents’ Method Claims................ 20 E. The Endo Patents Are Valid ..…obligation to respect the patent rights of the NDA holder. The FDA keeps a list of patents applicable to each…The four patents asserted against some or all of the Defendants are Endo’s United States Patent Nos. 8, External link to document
2015-03-27 91 STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216: Endo and Defendants…11 December 2012 1:12-cv-08985 830 Patent None District Court, S.D. New External link to document
2015-04-09 92 STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216: As used in the asserted…STIPULATION AND ORDER REGARDING U.S. PATENT NO. 8,309,122 AND U.S. PATENT NO. 8,329,216" dated March 27, 2015…asserted claims of U.S. Patent 8,329,216 ("the '216 patent"), the term "a release rate profile designed…11 December 2012 1:12-cv-08985 830 Patent None District Court, S.D. New External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Medtronic
Mallinckrodt
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.